Skip to main content
SAM CHUN DANG PHARM CO. LTD logo

SAM CHUN DANG PHARM CO. LTD — Investor Relations & Filings

Ticker · 000250 ISIN · KR7000250001 KO Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2025-02-07 Notice of Dividend Amou…
Country KR South Korea
Listing KO 000250

About SAM CHUN DANG PHARM CO. LTD

http://www.scd.co.kr/english/scd/index.…

SAM CHUN DANG PHARM CO. LTD. is a pharmaceutical company focused on the development, manufacturing, and sale of medications. The company specializes in ophthalmic products, establishing itself as a significant player in the generic eye care market. Its portfolio also extends to other therapeutic areas, including antibiotics and medications for the circulatory system. The company produces a range of ethical (prescription) and over-the-counter (OTC) drugs in both sterile and non-sterile forms. Manufacturing operations adhere to international quality standards, holding both US and EU Good Manufacturing Practice (GMP) certifications.

Recent filings

Filing Released Lang Actions
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Samchundang Pharm regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the approval process. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2025-02-07 Korean
불성실공시법인지정예고 (공시불이행)
Regulatory Filings Classification · 100% confidence The document is a formal notice from the Korea Exchange regarding the designation of Samchundang Pharm as an 'unfaithful disclosure corporation' due to a delay in reporting major management matters. This is a regulatory announcement concerning compliance and disclosure obligations, which falls under the category of general regulatory filings.
2025-01-21 Korean
기업설명회(IR)개최
Investor Presentation Classification · 98% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Non-deal Roadshow). It provides details such as the date, location, purpose, and the method of accessing the presentation materials. Since it is an announcement of an event and the availability of materials rather than the presentation itself, and it fits the regulatory announcement format for corporate events, it is classified as a Report Publication Announcement (RPA) or general regulatory filing. Given the specific nature of announcing an IR event, RPA is the most accurate fit.
2025-01-16 Korean
투자판단관련주요경영사항 (황반변성치료제(아일리아/주성분 : Aflibercept) 바이오시밀러 SCD411 2mg 저용량(Vial&PFS) 및 8mg 고용량(Vial&PFS)의 미국 및 라틴아메리카 6개국 독점 공급 및 판매계약 체결)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Samchundang Pharm regarding a major business decision: the signing of an exclusive supply and distribution agreement for a biosimilar drug (SCD411) in the US and Latin America. This type of disclosure, which details a significant commercial contract, is classified as a general regulatory announcement (RNS) in the absence of a more specific category like M&A or capital change.
2024-12-23 Korean
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory announcement from Samchundang Pharm regarding the setting of a record date for dividend distribution (shareholder register closure). It specifies the record date (2024-12-31) and the purpose (determining shareholders for the 81st fiscal year profit dividend). While it relates to dividends, it is not the final declaration of the dividend amount itself, but rather the procedural announcement of the record date. Given the options, this fits best as a regulatory filing regarding corporate actions.
2024-12-16 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a formal notice from Samchundang Pharm regarding the setting of a record date for the purpose of determining shareholders eligible to vote at the 81st Annual General Meeting. This type of regulatory disclosure, which informs the market about corporate actions like record dates for meetings, is classified as a general regulatory announcement.
2024-12-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.